Metabolic syndrome: updates on pathophysiology and management in 2021

G Fahed, L Aoun, M Bou Zerdan, S Allam… - International journal of …, 2022 - mdpi.com
Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin
resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis …

Anabolic–androgenic steroids: How do they work and what are the risks?

P Bond, DL Smit, W de Ronde - Frontiers in Endocrinology, 2022 - frontiersin.org
Anabolic–androgenic steroids (AAS) are a class of hormones that are widely abused for
their muscle-building and strength-increasing properties in high, nontherapeutic, dosages …

[HTML][HTML] PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

M Banach, P Burchardt, K Chlebus… - Archives of Medical …, 2021 - ncbi.nlm.nih.gov
Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

Nutraceuticals in the management of dyslipidemia: which, when, and for whom? Could nutraceuticals help low-risk individuals with non-optimal lipid levels?

AFG Cicero, F Fogacci, AP Stoian, M Vrablik… - Current atherosclerosis …, 2021 - Springer
Abstract Purpose of Review The aim of this review is to summarize the available clinical
efficacy and safety data related to the most studied and used lipid-lowering nutraceuticals …

[HTML][HTML] Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials

S Fogacci, F Fogacci, M Banach, ED Michos… - Clinical Nutrition, 2020 - Elsevier
Background Maternal vitamin D deficiency has been associated with an increased risk for
preeclampsia. Despite this, the current evidence regarding the efficacy of vitamin D …

Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials

F Fogacci, N Ferri, PP Toth, M Ruscica, A Corsini… - Drugs, 2019 - Springer
Aim Our aim was to assess the efficacy and safety of mipomersen through a systematic
review of the literature and a meta-analysis of the available clinical studies. Methods A …

[HTML][HTML] Red yeast rice for hypercholesterolemia

AFG Cicero, F Fogacci, M Banach - Methodist DeBakey …, 2019 - ncbi.nlm.nih.gov
The extract of red yeast rice (RYR) is the most effective cholesterol-lowering nutraceutical on
the market. In particular, its effectiveness is directly related to the amount of monacolin K …

[HTML][HTML] Bioactive compounds from herbal medicines to manage dyslipidemia

X Ji, S Shi, B Liu, M Shan, D Tang, W Zhang… - Biomedicine & …, 2019 - Elsevier
Dyslipidemia is a key risk factor for cardiovascular diseases, which are a major cause of
morbidity and mortality worldwide. However, despite the advancement of the treatment and …

Red yeast rice for the improvement of lipid profiles in mild-to-moderate hypercholesterolemia: a narrative review

AFG Cicero, F Fogacci, AP Stoian, PP Toth - Nutrients, 2023 - mdpi.com
Reducing low-density lipoprotein cholesterol (LDL-C) levels is a key target for lowering
cardiovascular risk and preventing atherosclerotic cardiovascular disease (ASCVD). Red …

Red yeast rice preparations reduce mortality, major cardiovascular adverse events, and risk factors for metabolic syndrome: A systematic review and meta− analysis

R Yuan, Y Yuan, L Wang, Q Xin, Y Wang… - Frontiers in …, 2022 - frontiersin.org
Background: Metabolic syndrome (MetS) is characterized by the cooccurrence of obesity,
insulin resistance, dyslipidaemia, and hypertension. Red yeast rice (RYR) preparations …